Literature DB >> 11523567

Analysis of p53 mutation and expression in pleomorphic xanthoastrocytoma.

C Giannini1, D Hebrink, B W Scheithauer, A P Dei Tos, C D James.   

Abstract

Pleomorphic xanthoastrocytoma (PXA) is a rare, superficially situated tumor that most frequently occurs in the temporal lobe of young adults and is often associated with seizures. It generally has a relatively favorable prognosis. Prior studies have shown that TP53 mutations may occur in up to 25% of PXAs, suggesting that PXA may have an etiology similar to diffuse astrocytoma rather than pilocytic astrocytoma. In the present study, we performed immunostaining for p53 protein and examined the mutation status of exons 5-8 of the p53 gene in 55 PXAs, 8 of which had undergone one or multiple recurrences. Of 55 primary PXAs, 35 (64%) showed staining in <1% of tumor cells, 15 (27%) in 1-10%, 4 (7%) in 11-50%, and only 1 (2%) in >50%. No significant increase in p53 protein expression was noted in recurrences, even when associated with increased histological anaplasia. We found a TP53 heterozygous mutation in exon 7 in 1 of 47 primary tumors that yielded useable DNA, and in its recurrence 3 years later. This tumor, a grade II PXA, did not show signs of anaplastic transformation at recurrence. Eleven additional recurrences from 7 patients, 5 of which showed signs of histological anaplasia, did not show TP53 mutations in exons 5-8. Based on our data, the p53 mutation appears to be an uncommon (2%) genetic event in PXA formation and does not appear to be involved in tumor progression. Consequently, our findings suggest that the genetic events that underlie PXA formation differ from those involved in diffuse astrocytoma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11523567     DOI: 10.1007/s100480100116

Source DB:  PubMed          Journal:  Neurogenetics        ISSN: 1364-6745            Impact factor:   2.660


  17 in total

1.  Epithelial and pseudoepithelial differentiation in glioblastoma and gliosarcoma: a comparative morphologic and molecular genetic study.

Authors:  Fausto J Rodriguez; Bernd W Scheithauer; Caterina Giannini; Sandra C Bryant; Robert B Jenkins
Journal:  Cancer       Date:  2008-11-15       Impact factor: 6.860

2.  Pleomorphic Xanthoastrocytoma: Natural History and Long-Term Follow-Up.

Authors:  Cristiane M Ida; Fausto J Rodriguez; Peter C Burger; Alissa A Caron; Sarah M Jenkins; Grant M Spears; Dawn L Aranguren; Daniel H Lachance; Caterina Giannini
Journal:  Brain Pathol       Date:  2014-12-05       Impact factor: 6.508

Review 3.  Pathologic and molecular aspects of anaplasia in circumscribed gliomas and glioneuronal tumors.

Authors:  Elisabet Pujadas; Liam Chen; Fausto J Rodriguez
Journal:  Brain Tumor Pathol       Date:  2019-03-11       Impact factor: 3.298

4.  Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177.

Authors:  Paul D Brown; Sunil Krishnan; Jann N Sarkaria; Wenting Wu; Kurt A Jaeckle; Joon H Uhm; Francois J Geoffroy; Robert Arusell; Gaspar Kitange; Robert B Jenkins; John W Kugler; Roscoe F Morton; Kendrith M Rowland; Paul Mischel; William H Yong; Bernd W Scheithauer; David Schiff; Caterina Giannini; Jan C Buckner
Journal:  J Clin Oncol       Date:  2008-10-27       Impact factor: 44.544

5.  Cerebral anaplastic pleomorphic xanthoastrocytoma with meningeal dissemination at first presentation.

Authors:  Alphonse Lubansu; Sandrine Rorive; Philippe David; Eric Sariban; Roland Seligmann; Jacques Brotchi; Benoit Pirotte
Journal:  Childs Nerv Syst       Date:  2003-12-11       Impact factor: 1.475

Review 6.  Pathology and molecular genetics of astrocytic gliomas.

Authors:  Guido Reifenberger; Vincent Peter Collins
Journal:  J Mol Med (Berl)       Date:  2004-10       Impact factor: 4.599

7.  Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.

Authors:  Brett L Carlson; Patrick T Grogan; Ann C Mladek; Mark A Schroeder; Gaspar J Kitange; Paul A Decker; Caterina Giannini; Wenting Wu; Karla A Ballman; C David James; Jann N Sarkaria
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-09-01       Impact factor: 7.038

8.  P53 codon 72 Arg/Pro polymorphism and glioma risk: an updated meta-analysis.

Authors:  Fang He; Yi Xia; Huafeng Liu; Jin Li; Chao Wang
Journal:  Tumour Biol       Date:  2013-07-17

Review 9.  Aggressive behavior and anaplasia in pleomorphic xanthoastrocytoma: a plea for a revision of the current WHO classification.

Authors:  Nesibe Kahramancetin; Tarik Tihan
Journal:  CNS Oncol       Date:  2013-11

Review 10.  Molecular neuropathology of gliomas.

Authors:  Markus J Riemenschneider; Guido Reifenberger
Journal:  Int J Mol Sci       Date:  2009-01-07       Impact factor: 6.208

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.